![Renejix CDMO Partner for Small Molecule Oral Dosage Forms](https://www.pharmacompass.com/image/flap/renejix-w35-desktop-header-01gif-33629.gif)
![Renejix CDMO Partner for Small Molecule Oral Dosage Forms](https://www.pharmacompass.com/image/flap/renejix-w35-mob-header-01gif-17728.gif)
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
0
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
1. 40-o-(2-ethoxyethyl)rapamycin
2. 42-o-(2-ethoxyethyl) Rapamycin
3. Biolimus A9
4. Rapamycin, 42-o-(2-ethoxyethyl)-
5. Trm-986
1. Biolimus A9
2. Trm 986
3. Trm-986
4. 42-o-(2-ethoxyethyl) Rapamycin
5. 40-o-(2-ethoxyethyl)rapamycin
6. 851536-75-9
7. Rapamycin, 42-o-(2-ethoxyethyl)-
8. U36pgf65jh
9. Biolimus-a9
10. A9
11. Umirolimus [inn]
12. Umirolimus [usan:inn]
13. Umirolimus [usan]
14. Unii-u36pgf65jh
15. Umirolimus [who-dd]
16. Ba-9
17. Trm986
18. Chembl2107380
19. Schembl17117902
20. Ex-a3593
21. Zinc169677041
22. Db15527
23. Hy-122402
24. Cs-0085037
25. Q7881588
26. A-9
Molecular Weight | 986.3 g/mol |
---|---|
Molecular Formula | C55H87NO14 |
XLogP3 | 6.8 |
Hydrogen Bond Donor Count | 2 |
Hydrogen Bond Acceptor Count | 14 |
Rotatable Bond Count | 11 |
Exact Mass | 985.61265645 g/mol |
Monoisotopic Mass | 985.61265645 g/mol |
Topological Polar Surface Area | 194 Ų |
Heavy Atom Count | 70 |
Formal Charge | 0 |
Complexity | 1840 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 15 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 4 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
Anti-Inflammatory Agents
Substances that reduce or suppress INFLAMMATION. (See all compounds classified as Anti-Inflammatory Agents.)
Immunosuppressive Agents
Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging. (See all compounds classified as Immunosuppressive Agents.)